JPRN-jRCT2071220109进行中（未招募）1 期
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Axatilimab When Administered by Intravenous Infusion to Healthy Japanese Participants
eda Eiji0 个研究点目标入组 20 人开始时间: 2023年2月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 55age old（—）
- 性别
- Male
入选标准
- •1. Male aged 18 to 55 years, inclusive at the time of signing the ICF.
- •2. Body weight defined in protocol inclusive at the time of screening.
- •3. No clinically significant findings on screening evaluation.
- •4. Male participants with reproductive potential must agree to take appropriate precautions to avoid fathering children from screening through 90 days after the dose of study drug on Day 1 and must refrain from donating sperm during this period.
排除标准
- •1. History of clinically significant respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease.
- •2. History of cardiovascular, cerebrovascular, or peripheral vascular thrombotic disease or history of uncontrolled hypertension.
- •3. Blood pressure > 140/90 mm Hg at screening, confirmed by repeat testing.
- •4. History of rheumatologic/autoimmune disorders, except for minor eczema and rosacea.
- •5. Resting pulse < 40 bpm or > 100 bpm at screening, confirmed by repeat testing.
- •6. History or presence of an abnormal ECG before initial dose administration that, in the investigator's opinion, is clinically significant.
- •7. History of malignancy within 5 years of screening, with the exception of cured basal cell or squamous cell carcinoma of the skin.
- •8. Any major surgery within 24 weeks of screening.
- •9. Donation of >= 200 mL of whole blood within 4 weeks of screening or >= 400 mL of whole blood within 12 weeks of screening to a blood bank or for a clinical study (except a screening visit).
- •10. Blood transfusion within 4 weeks of check-in.
- •11. Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
- •12. Positive test for active HBV or HCV infection or risk of reactivation of HBV or HCV. If HBsAg is negative and HBcAb and/or HBsAb is positive, HBV DNA should be measured. If HBV DNA is negative, the participant may be enrolled in the study with close monitoring of HBV activities. Participants positive for HCV antibody will be eligible if they are negative for HCV RNA.
- •13. Positive test for HIV.
- •14. History of alcoholism within 3 weeks of screening.
- •15. Positive breath or urine test for ethanol or positive urine screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
- •16. Current treatment before the first dose of study drug with another investigational medication, or current enrollment in another investigational drug study.
- •17. History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
- •18. Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
- •19. History of tobacco- or nicotine-containing product use within 4 weeks of screening. However, use of nicotine-containing products that are the equivalent to <= 2 cigarettes per week may be permitted at the discretion of the investigator.
- •20. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- •21. Positive COVID-19 PCR test at the check-in.
研究者
相似试验
已完成
1 期
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Japanese ParticipantsJPRN-jRCT2071210079eda Eiji30
已完成
1 期
A study to investigate ARG-007 in Healthy VolunteersStroke - IschaemicStrokeACTRN12622001209785Argenica Therapeutics Ltd.32
尚未招募
1 期
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of increasing oral doses of INCB106385 in healthy adult participants, and the effect of food on pharmacokinetics, as well as drug interaction with a Proton Pump Inhibitor (PPI) esomeprazole.ACTRN12620000630910Incyte Corporation84
尚未招募
1 期
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of increasing oral doses of INCB099280 in healthy adult participants, and the effect of food on pharmacokineticsSolid TumorsCancer - Other cancer typesACTRN12619001529134Incyte Corporation72
已完成
1 期
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First in Human Study of PRAX-330 to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses in Healthy SubjectsEpilepsyACTRN12617001512314Praxis Precision Medicines Australia Pty Ltd68